Cohort of Patients With Chronic Myelomonocytic Leukemia

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT07512882
Status
Recruiting
Apply to this trial

Conditions

  • Leukemia
  • Myelomonocytic Leukemia, Chronic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sampling — BIOLOGICAL
    Blood samples taken as part of a scheduled assessment within the context of medical care * Standard sample: 2 x 10 mL EDTA tubes * For the initial assessment: 1 x 10 mL dry tube At the request of the research teams: one EDTA tube may be replaced by a heparinised or citrated tube, depending on the planned research. Bone marrow samples, taken during a scheduled myelogram as part of medical care * Myelogram: 1 x 2 mL EDTA tube In exceptional cases, during a scheduled surgical procedure, a tissue sample will be considered in consultation with the surgeon (affected tissue, surrounding healthy tissue).

Study Details

A prospective, non-interventional study involving the collection of biological samples with associated anonymised data. Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.

Key Dates

First listed
Apr 6, 2026
Start date
May 5, 2026
Status verified
May 2026
Primary completion
Mar 31, 2040
Completion
Mar 31, 2040

Study Design

Enrollment
5,000 participants (estimated)

Arms

  • Arm: Cohort of patients with chronic myelomonocytic leukemia

Primary Outcome Measure

Understanding the pathophysiology of chronic myelomonocytic leukaemia [ Time Frame: through study completion, an average of 15 years ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies